Women have the added complication that several currently available AEDs increase the risk to the fetus, including birth defects, lowered IQ and low birth weight. Most of these drugs are labeled by the FDA as a potential risk to the fetus, and three of these drugs (valproate, carbamazepine, phenytoin) have been labeled for use only when justified that the therapeutic need outweighs risk to the fetus based on registry data.
According to Decision Resources, in 2014 approximately five million people were under treatment for epilepsy in the United States, Europe and Japan. Despite the many available AEDs, approximately 30 to 35% of patients do not attain acceptable seizure control either with single drug or multiple drug therapy. Furthermore, medications with significant side effects or dosing regimens that undermine compliance make it difficult for patients to achieve and maintain seizure free status. For these reasons there is a need for new AEDs with novel mechanisms of action and
improved side effect profiles that can maintain seizure control with chronic administration for people with drug-resistant epilepsy.
The successful introduction of Vimpat by UCB is the most recent example of market acceptance of a new AED with a novel mechanism. Vimpat was approved in the United States and European Union in 2008, and has reported that it achieved global sales of approximately €471 million in 2014. Several other successfully marketed AEDs experienced similar sales levels with similar duration of time on the market. UCB has reported that it expects Vimpat to achieve over €1.2 billion in peak sales globally.

### Language ###
English

### Assessment ###
We could ask about the sales figures of Vimpat, a specific epilepsy drug, in 2014.

### Query ###
What were Vimpat's global sales in 2014?
What were Vimpat's global sales in 2014?